Article
Gastroenterology & Hepatology
Anthony Lembo, Shahnaz Sultan, Lin Chang, Joel J. Heidelbaugh, Walter Smalley, G. Nicholas Verne
Summary: This article presents medication management guidelines for irritable bowel syndrome (IBS). The guidelines provide 8 recommendations for the pharmacological treatment of IBS-D patients, and evaluate the evidence and certainty of different medications.
Review
Pharmacology & Pharmacy
Di Qin, Qing-Feng Tao, Shi-Le Huang, Min Chen, Hui Zheng
Summary: This study compared the efficacy of eluxadoline and antispasmodics in the treatment of irritable bowel syndrome (IBS). The results showed that eluxadoline was as effective as antispasmodics in relieving abdominal pain, but had more reported adverse events. Therefore, antispasmodics remain the first choice for the treatment of IBS.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Agnieszka Chlebicz-Wojcik, Katarzyna Slizewska
Summary: Irritable bowel syndrome is not life-threatening but significantly impacts quality of life and economic loss. Research focuses on the role of intestinal microbiota in disease development, with an emphasis on therapies modulating the microbiota such as probiotics, prebiotics, and synbiotics. Most studies have focused on probiotics, but there are also promising results from studies on prebiotics and synbiotics.
Review
Pharmacology & Pharmacy
Marcella Pesce, Maria Giovanna Puoti, Anna Rybak, Marta Andreozzi, Eugenia Bruzzese, Giovanni Sarnelli, Osvaldo Borrelli
Summary: Pediatric irritable bowel syndrome is a common functional gastrointestinal disorder characterized by recurrent abdominal pain and altered bowel habits. The overall treatment response rate may be unsatisfactory without a multidisciplinary approach. Evidence involving pediatric populations is often based on open label or retrospective studies and may not specifically target irritable bowel syndrome.
EXPERT OPINION ON PHARMACOTHERAPY
(2022)
Article
Physiology
Yun-zhou Shi, Qing-feng Tao, Di Qin, Min Chen, Shu-guang Yu, Hui Zheng
Summary: Acupuncture was found to be more effective than antispasmodics in relieving abdominal pain and improving global IBS symptoms, with lower rates of adverse events. Cimetropium, drotaverine, and acupuncture were all superior over placebo in improving abdominal pain.
FRONTIERS IN PHYSIOLOGY
(2022)
Article
Medicine, General & Internal
Samira Ait Abdellah, Julien Scanzi, Caroline Gal, Marc Martin, Marc Beck, Veronica Ojetti
Summary: This multicenter study investigated the effects of L. gasseri LA806 supplementation on IBS symptoms and quality of life. The study found that the majority of patients experienced a significant decrease in abdominal pain and improvement in overall IBS symptoms and quality of life after 4 weeks of supplementation.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Gastroenterology & Hepatology
Vivek C. Goodoory, Mais Khasawneh, Christopher J. Black, Eamonn M. M. Quigley, Paul Moayyedi, Alexander C. Ford
Summary: This article conducted a meta-analysis to study the efficacy of probiotics in the treatment of irritable bowel syndrome (IBS). The study found that certain combinations of probiotics or strains may be beneficial for IBS, but the certainty of the evidence was low.
Review
Gastroenterology & Hepatology
Joelle BouSaba, Wassel Sannaa, Michael Camilleri
Summary: Pain relief in patients with IBS remains a significant challenge, but interventions including diet and pharmacological treatments offer hope for more effective therapeutic options. Recent advances in the field indicate a potential expansion of the therapeutic arsenal for pain in IBS.
NEUROGASTROENTEROLOGY AND MOTILITY
(2022)
Review
Immunology
Tao Zhang, Cunzheng Zhang, Jindong Zhang, Feng Sun, Liping Duan
Summary: This network meta-analysis found that B.coagulans exhibited significant efficacy in treating IBS patients, L.plantarum ranked first in improving quality of life, and L.acidophilus had the lowest incidence of adverse events. Treatment length significantly influenced the efficacy of probiotics in improving abdominal pain and straining.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2022)
Article
Nutrition & Dietetics
Gyeol Seong, Seungbaek Lee, Yang Won Min, Yeon Sil Jang, Hong Seog Kim, Eui-Joong Kim, So-Young Park, Cheol-Hyun Kim, Dong Kyung Chang
Summary: The study found that heat-killed L. casei DKGF7 can improve stool consistency in a rat IBS model, indicating a potential therapeutic strategy for IBS treatment.
Article
Microbiology
Joann Phan, Divya Nair, Suneer Jain, Thibaut Montagne, Demi Valeria Flores, Andre Nguyen, Summer Dietsche, Saurabh Gombar, Philip Cotter
Summary: Irritable bowel syndrome (IBS) is characterized by abdominal discomfort and irregular bowel movements, with the gut microbiome posited to play a significant role. This study analyzed stool samples from individuals with IBS and without IBS and found differences in microbial features, with synbiotic supplementation showing potential to impact these features. Further research is needed to determine the relationship between microbiome changes and improvement in IBS symptoms.
Letter
Gastroenterology & Hepatology
Yuka Ikeda, Kurumi Taniguchi, Haruka Sawamura, Ai Tsuji, Satoru Matsuda
Summary: Irritable bowel syndrome is an important health concern that may be linked to alterations in the microbiota of the gut-brain axis. Dietary intake can contribute to the production of D-amino acids, which play key roles in cellular physiological processes against oxidative stresses. The gut microbiota may have significant effects on emotional stability through the action of D-amino acids.
WORLD JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Gastroenterology & Hepatology
Giovanni Marasco, Cesare Cremon, Maria Raffaella Barbaro, Giulia Cacciari, Francesca Falangone, Anna Kagramanova, Dmitry Bordin, Vasile Drug, Egidia Miftode, Pietro Fusaroli, Salem Youssef Mohamed, Chiara Ricci, Massimo Bellini, Mohammed Masudur Rahman, Luigi Melcarne, Javier Santos, Beatriz Lobo, Serhat Bor, Suna Yapali, Deniz Akyol, Ferdane Pirincci Sapmaz, Yonca Yilmaz Urun, Tugce Eskazan, Altay Celebi, Huseyin Kacmaz, Berat Ebik, Hatice Cilem Binicier, Mehmet Sait Bugdayci, Munkhtsetseg Banzragch Yagci, Husnu Pullukcu, Berrin Yalinbas Kaya, Ali Tureyen, Ibrahim Hatemi, Elif Sitre Koc, Goktug Sirin, Ali Riza Caliskan, Goksel Bengi, Esra Ergun Alis, Snezana Lukic, Meri Trajkovska, Keren Hod, Dan Dumitrascu, Antonello Pietrangelo, Elena Corradini, Magnus Simren, Jessica Sjoelund, Navkiran Tornkvist, Uday C. Ghoshal, Olga Kolokolnikova, Antonio Colecchia, Jordi Serra, Giovanni Maconi, Roberto De Giorgio, Silvio Danese, Piero Portincasa, Antonio Di Sabatino, Marcello Maggio, Elena Philippou, Yeong Yeh Lee, Daniele Salvi, Alessandro Venturi, Claudio Borghi, Marco Zoli, Paolo Gionchetti, Pierluigi Viale, Vincenzo Stanghellini, Giovanni Barbara
Summary: This study aimed to evaluate the prevalence of gastrointestinal symptoms and post-COVID-19 disorders of gut-brain interaction among hospitalized patients with SARS-CoV-2 infection. The results showed that patients with COVID-19 had higher rates of gastrointestinal symptoms on hospital admission and lower rates of constipation and hard stools at 12 months post-infection compared to the control group. Additionally, the rate of irritable bowel syndrome was significantly higher in patients with COVID-19 than in controls.
Article
Gastroenterology & Hepatology
Tao Bai, Zhiyue Xu, Peijun Xia, Yichao Feng, Bing Liu, Hongling Liu, Yunwang Chen, Guangjun Yan, Bin Lv, Zaihong Yan, Ning Dai, Yanqin Long, Wei Wei, Zhihong Shi, Xiaoqing Li, Xiucai Fang, Huibin Gao, Lingzhi Qi, Xiaohua Hou
Summary: This study evaluated the short-term efficacy of Bifidobacterium quadruple viable tablet in patients with diarrhea-predominant irritable bowel syndrome (IBS) and explored factors associated with response to probiotics. After 4 weeks of treatment, the response rate in the probiotics group was significantly higher compared to the placebo group. Patients with higher abdominal pain scores were more likely to respond to the probiotics. The probiotics also increased the abundance of bacteria producing short-chain fatty acids (SCFAs) and the concentration of SCFAs in feces.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2023)
Review
Microbiology
Tarek Mazzawi
Summary: Research suggests that manipulating gut microbiota can improve symptoms of irritable bowel syndrome (IBS), with dietary management and other approaches showing promise in changing gut composition and alleviating IBS symptoms. However, more research is needed to identify the exact mixture of beneficial bacteria.
Letter
Gastroenterology & Hepatology
Conchubhair Winters, Alexander Charles Ford
Review
Gastroenterology & Hepatology
Brigida Barberio, Pierfrancesco Visaggi, Edoardo Savarino, Nicola de Bortoli, Christopher J. Black, Alexander C. Ford
Summary: This study conducted a network meta-analysis to evaluate the efficacy and safety of different medical therapies for endoscopy-negative reflux disease. The results showed that proton pump inhibitors (PPIs) are superior to other drugs in treating this condition. Future research should focus on better patient classification and investigating the efficacy of other drugs.
NEUROGASTROENTEROLOGY AND MOTILITY
(2023)
Article
Gastroenterology & Hepatology
Vivek C. Goodoory, Cho Ee Ng, Christopher J. Black, Alexander C. Ford
Summary: This study examined willingness to pay for medications among individuals with irritable bowel syndrome (IBS). The results showed that women and individuals with an annual income of 30,000 pounds or more were more likely to be willing to pay for medication. In addition, individuals with lower IBS-related quality of life were more willing to pay for a medication that could improve their symptoms.
NEUROGASTROENTEROLOGY AND MOTILITY
(2023)
Review
Gastroenterology & Hepatology
Shahida Din, Christian P. Selinger, Christopher J. Black, Alexander C. Ford
Summary: A network meta-analysis was conducted to examine the risk of Herpes zoster infection associated with biologics and small molecules used to treat inflammatory bowel disease (IBD). The results showed that Janus kinase inhibitors, particularly tofacitinib, were most likely to increase the risk of Herpes zoster infection, and the risk increased with higher doses.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Gastroenterology & Hepatology
Vivek C. C. Goodoory, Elspeth A. A. Guthrie, Cho E. E. Ng, Christopher J. J. Black, Alexander C. C. Ford
Summary: Irritable bowel syndrome (IBS) has a substantial impact on the quality of life of affected individuals, and the negative impact is worse than observed in some severe chronic organic conditions.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Review
Gastroenterology & Hepatology
Maria Rosa Ingrosso, Michael Camilleri, Jan Tack, Gianluca Ianiro, Christopher J. Black, Alexander C. Ford
Summary: This study evaluated the efficacy and safety of drugs for gastroparesis through a network meta-analysis. The results showed that oral dopamine antagonists and tachykinin-1 antagonists were more effective than placebo. For individual symptoms, oral metoclopramide showed good efficacy for nausea, fullness, and bloating. However, the confidence in the evidence for most comparisons was low to moderate, indicating a need for more effective therapies for gastroparesis.
Article
Gastroenterology & Hepatology
Brigida Barberio, David J. Gracie, Christopher J. Black, Alexander C. Ford
Summary: In this study, the authors conducted a systematic review and meta-analysis to evaluate the impact of criteria used to define CD activity at study entry and the time point used to confirm efficacy on the therapeutic gain of active drug over placebo. The results showed that both factors appeared to be important in maximizing the treatment effect of active drug compared to placebo.
INFLAMMATORY BOWEL DISEASES
(2023)
Editorial Material
Gastroenterology & Hepatology
Vivek C. Goodoory, Elspeth A. Guthrie, Cho Ee Ng, Christopher J. Black, Alexander C. Ford
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Gastroenterology & Hepatology
Vivek C. Goodoory, Cho E. Ng, Christopher J. Black, Alexander C. Ford
Summary: This study compared the characteristics of individuals with irritable bowel syndrome (IBS) reporting faecal incontinence (FI) with those who do not report FI. The results showed that individuals with FI were older, more likely to have IBS-D, had lower education levels and incomes, reported more urgency and more severe IBS and psychological symptoms, had lower quality of life scores, and higher healthcare costs.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Gastroenterology & Hepatology
Kee-Huat Chuah, Christopher J. Black, Vincent Tee, Sze-Zee Lim, Wen-Xuan Hian, Nur-Fazimah Sahran, Yeong-Yeh Lee, Sanjiv Mahadeva, Alexander C. Ford
Summary: By comparing IBS patients from the UK and Malaysia, it was found that UK patients were more likely to consume alcohol, had more frequent symptoms such as pain, bloating, and meal-related issues, higher symptom scores, greater limitation of activities, and a higher likelihood of reporting abnormal anxiety. UK patients also had higher levels of perceived stress, gastrointestinal symptom-specific anxiety, and somatoform symptom-reporting.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Editorial Material
Gastroenterology & Hepatology
Vivek C. Goodoory, Cho Ee Ng, Christopher J. Black, Alexander C. Ford
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Editorial Material
Gastroenterology & Hepatology
David Gunn, Alexander Ford, Amanda Farrin, Robin Spiller
Summary: This article is related to the papers by Gunn et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Letter
Gastroenterology & Hepatology
Vivek C. Goodoory, Elspeth A. Guthrie, Cho Ee Ng, Christopher J. Black, Alexander C. Ford
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Letter
Gastroenterology & Hepatology
Vivek C. Goodoory, Cho E. Ng, Christopher J. Black, Alexander C. Ford
Summary: This article is associated with Goodoory et al papers. Click the link to access these articles.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Letter
Gastroenterology & Hepatology
Alexander C. Ford, Colin W. Howden
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)